PIK3CA and head and neck squamous cell carcinoma: One of the most “actionable” target in this pathway is the activating gain of function PIK3CA mutations, as PI3K inhibitors of different classes, either alone or in combination with other targeted agents, are in active development in HNSCC (Tables 1 and 2).